Rapid Novor

Exciting News! We’re thrilled to announce the publication of our latest research in Nature Communications:  “𝗗𝗲 𝗡𝗼𝘃𝗼 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 𝗼𝗳 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗳𝗼𝗿 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗡𝗲𝘂𝘁𝗿𝗮𝗹𝗶𝘇𝗶𝗻𝗴 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗶𝗻 𝗛𝘂𝗺𝗮𝗻 𝗣𝗹𝗮𝘀𝗺𝗮 𝗣𝗼𝘀𝘁 𝗦𝗔𝗥𝗦-𝗖𝗼𝗩-𝟮 𝗩𝗮𝗰𝗰𝗶𝗻𝗮𝘁𝗶𝗼𝗻.” This study demonstrates how de novo antibody sequencing—identifying antibodies directly from blood without relying on genetic databases—uncovers unique and functional antibodies in serum that might otherwise be missed. Our talented multidisciplinary team, including Thierry Le Bihan, Teresa Nunez de Villavicencio Diaz, Chelsea Reitzel, Victoria Lange, Minyoung (Emily) Park, Emma Beadle, Lin W., Marko J. Rosalin Dubois, Amber Couzens, Jin D., Xiaobing Han, Qixin L., and Bin Ma, made significant discoveries: • We generated 12 recombinant antibodies, with six found exclusively through de novo sequencing, revealing antibodies not present in B-cell data. • Six recombinant mAbs showed affinities similar to or better than the original polyclonal antibody, with four of the strongest binders obtained via de novo sequencing. • Antibodies discovered using both de novo sequencing and IgSeq exhibited varied neutralization activity in in-vitro and cell-based assays. Our findings highlight that the circulating B-cell repertoire does not capture all antibody present in circulation, making de novo protein sequencing a vital complementary tool in antibody discovery for novel therapeutics. Check out the paper here: https://lnkd.in/gZeKGk_j Read our press release here: https://lnkd.in/gCpevFau #AntibodyDiscovery #PolyclonalSequencing #ProteinSequencing #Proteogenomics #AntibodyDevelopment #DrugDiscovery #Published #NatureCommunications

All we want for Christmas... is you (to bind specifically)! 🎄✨ Wishing everyone a joyful and safe holiday season! #HappyHolidays

We celebrated the season with our final company gathering at our holiday party! The evening was filled with delicious food, refreshing drinks, fun games, and plenty of laughter. Happy Holidays from our team to yours! #RapidNovor #HolidayParty #HappyHolidays

As the year winds down, we’re curious how our fellow scientists plan to recharge. Whether it’s relaxation, family time, lab work, or something in between, let us know! #LabLife

Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) are often overexpressed in certain tumor types. Tusamitamab ravtansine, an antibody-drug conjugate, specifically targets human CEACAM5. To better understand this specificity, researchers Anand Kumar, Alexey Rak, and colleagues at Sanofi mapped the epitope-paratope interface between CEACAM5 and tusamitamab’s antigen-binding fragment. Using a combination of advanced techniques—hydrogen/deuterium exchange mass spectrometry (HDX-MS), surface plasmon resonance (SPR), and cryo-EM—they gained a detailed understanding of the interaction. Cryo-EM provided high-resolution structural insights into the CEACAM5 antigen, while the extensive sequence coverage achieved with HDX-MS offered robust confidence in the binding epitope, ensuring no critical regions were overlooked. Check out the paper here: https://lnkd.in/eF4tQ5nt Looking to map the binding epitopes of your key antibody candidates with HDX-MS? Contact us to learn more: https://lnkd.in/gi533cdX #AntibodyTherapeutics #ADCDevelopment #Proteomics #EpitopeMapping #HDXMS 

Jennifer Crha and Olga Kapustina are at booth #410 at Antibody Engineering & Therapeutics! #AntibodyDiscovery #Therapeutics #AET2024

How many polyclonal antibodies are you currently using in your research or products? Let us know in the comments how these antibodies are supporting your work! 👇  #PolyclonalAntibodies #AntibodyDiscovery #Research

HDX-MS and in silico modeling of antibody-antigen interactions form a powerful complementary approach, ideal for antibody discovery campaigns to screen and select confident, functional antibody candidates. Check out our on-demand webinar, in partnership with MAbSilico on Integrating AI and HDX-MS for Antibody Epitope Mapping. Check it out here: https://hubs.li/Q02_pDb70 #HDXMS #EpitopeMapping #AIDrugDiscovery #AntibodyDiscovery #ML

As 2024 wraps up, we’re celebrating a year of milestones, growth, and collaboration. A huge thank you to our amazing team, partners, and clients for being part of this journey. Here’s to even greater success in 2025! 🥂✨ #RapidNovorWrapped #2024Recap #Hello2025

B cell sequencing methods have paved the way for understanding immune diversity, but are they capturing the full picture? In our latest article, we compare traditional B cell sequencing methods (BCR-seq and scBCR-seq) with de novo polyclonal sequencing of proteins — a cutting-edge approach that captures the full diversity of antibodies directly from serum using mass spectrometry and machine learning. Check out the article here: https://lnkd.in/gVihiuAJ #AntibodyDiscovery #PolyclonalSequencing #Proteomics #MassSpectrometry #LifeSciencesInnovation #AdaptiveImmunity